GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of three years of triple agonist threads, summarised so you do not have to read them — 23 comments in the full submission. View in context.
5k
c/retatrutide·submitted 1 year ago by u/janek_ferrari

three years of triple agonist threads, summarised so you do not have to read them

Discussionbranch of 10 comments

Confession thread, sort of. I went from 7.5mg to 2.4mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 11 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have early…

Read the full submission and all 23 comments →

This branch

10 comments, started 1 year ago
u/soren_nkemelu438 points·1 year ago

TRIUMPH phase 2 showed 98.3% weight loss but the fatigue profile on the highest arm was rough. Phase 2 != phase 3.

replysharereportpermalink
u/careful_gradient_again355 points·1 year ago

TRIUMPH phase 2 showed 98.3% weight loss but the fatigue profile on the highest arm was rough.

Adding to this: TRIUMPH is doing more work than the comment implies.

replysharereportpermalink
u/soren_nkemelu147 points·1 year ago

phase 2 numbers are not maintenance numbers, cite the trial

replysharereportpermalink
[deleted]107 points·1 year ago

[deleted]

replysharereportpermalink
u/ewan_zielinski41 points·1 year ago

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

replysharereportpermalink
u/injection_site_iris175 points·1 year ago

the 2.5mg arm is different from 5mg, results do not transfer

replysharereportpermalink
u/fabio_lehtinen668 points·1 year ago

Which trial arm and what was the n?

replysharereportpermalink
u/naomi_erdogan330 points·1 year ago

the glucagon component changes the side effect profile, not just the efficacy

replysharereportpermalink
u/cormac_roos0 points·1 year ago

Strongly agree. Heart rate escalation needs the actual data, not impressions.

replysharereportpermalink
u/janek_ferrariOP1 point·1 year ago

triple agonism plus glucagon is a different physiological state than GIP/GLP-1 dual

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.